| [1] |
No authors listed. ASHP statement on the use of medications for unlabeled uses[J]. Am J Hospital Pharm, 1992, 49(8): 2006-2008.
|
| [2] |
Zheng Z, Xu F. Chinese pharmacists propose patient consent for unlabeled use of medications[J]. J Manag Care Pharm,2010,16(8): 640.
|
| [3] |
Almashat S,Preston C,Waterman T,et al. Rapidly increasing criminal and civil monetary penalties against the pharmaceutical industry: 1991 to 2010[EB/OL]. [2014-02-20]. http: / /www.citizen.org/hrg1924.
|
| [4] |
Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians[J]. Arch Intern Med, 2006,166(9): 1021-1026.
|
| [5] |
Barletta JF, Lat I, Micek ST, et al. Off-label use of gastrointestinal medications in the intensive care unit[EB/OL]. [2014-02-20]. http: / /jic. sagepub. com/content/early/2013/12/19/0885066613516574.long.
|
| [6] |
Conti RM, Bernstein AC, Villaflor VM, et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists[J]. J Clin oncol,2013,31(9): 1134-1139.
|
| [7] |
American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications[J]. J Clin Oncol,2006,24(19): 3206-3208.
|
| [8] |
Wang W, Zhu M, Guo D, et al. Off-label and off-NCCN guidelines uses of antineoplastic drugs in China[J]. Iran J Public Health,2013,42(5): 472-479.
|
| [9] |
Stafford RS. Off-label use of drugs and medical devices: a review of policy implications[J]. Clin Pharmacol Ther, 2012,91(5): 920-925.
|
| [10] |
Dal Pan GJ. Monitoring the safety of medicines used off-label[J]. Clin Pharmacol Ther,2012,91(5): 787-795.
|
| [11] |
徐树明. 2012 全球医药大事记[N]. 医药经济报.2012-12-26.
|
| [12] |
Medicines and Healthcare Products Regulatory Agency. Offlabel or unlicensed use of medicines: prescribers ’responsibilities[EB/OL]. [2013-04-14]. http: / /www. mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087990.
|
| [13] |
张伶俐,李幼平,曾力楠,等. 15 国超说明书用药政策的循证评价[J].中国循证医学杂志,2012,12(4): 426-435.
|
| [14] |
NHS Foundation Trust. Guidelines for unlicensed and off-label use of medicines [EB/OL]. http: / /www. cddmedicinesmanagement.nhs.uk/documents/Prescribing/Guidelines/Central Nervous System/TEWV Guidelines for Unlicensed and Off Label Use of Medicine.pdf.
|
| [15] |
Emmerich J, Dumarcet N, Lorence A. France’ s new framework for regulating off-label drug use[J]. N Engl J Med,2012,367(14): 1279-1281.
|
| [16] |
Le Jeunne C, Billon N, Dandon A, et al. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? [J]. Therapie, 2013,68(4): 225-239.
|
| [17] |
葛饮南, 邵蓉. 由“超说明书用药”思考药品的科学监管[J]. 中国药事,2012,26(12): 1322-1325.
|
| [18] |
U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act (FD&C Act)[EB/OL].[2014-02-20]. http: / /www. fda. gov/RegulatoryInformation/Legislation/FederalFood DrugandCosmeticActFDCAct/default.htm.
|
| [19] |
Frattarelli DA, Galinkin JL, Green TP. Off-label use of drugs in children[J]. Pediatrics,2014,133(3): 563-567.
|
| [20] |
国家卫生和计划生育委员会. 卫生部国家中医药管理局总后勤部卫生部关于印发《医疗机构药事管理规定》的通知(卫医政发〔2011〕11 号)[EB/OL]. [2014-02-20]. http: / /www.moh.gov.cn/yzygj/s3593/201103/4119b5de252 d45ac916 d420e0d30fda7.shtml.
|
| [21] |
四川省药学会临床药学专业委员会. 四川省药学会超说明书用药专家共识[EB/OL]. [2014-02-20]. http: / /www.scypzc.com/fabu/xhgz/2013731101249.htm.
|
| [22] |
Miller JL. Rules set for dissemination of off-label-use information[J]. Am J Health Syst Pharm,1999,56(3): 204.
|
| [23] |
U.S. Food and Drug Administration. FDA guidance for industry-good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices (2009) [EB/OL]. [2014-02-20].http: / /www.fda.gov/RegulatoryInformation/Guidances/ucm125126.htm.
|
| [24] |
U.S. Food and Drug Administration. Measures undertaken to address concerns about marketing of umapproved drugs (2010)[EB/OL]. [2014-02-20]. http: / /www. fda. gov/drugs/drugsafety/drugsafetypodcasts/ucm079099.htm.
|
| [25] |
Johnson PE. Pharmaceutical reimbursement: an overview[J].Am J Health Syst Pharm,2008,65(2 Suppl 1): S4-10.
|
| [26] |
Kaa K. Medicare challenges and solutions—reimbursement issues in treating the patient with colorectal cancer[J]. J Manag Care Pharm,2007,13(6 Suppl C): S19-26.
|
| [27] |
American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications[J]. J Clin Oncol,2006,24(19): 3206-3208.
|
| [28] |
Cheng AC,Robinson PM,Harvey K. Off-label use of medicines: consensus recommendations for evaluating appropriateness[J].Med J Aust,2007,186(7): 379-380.
|
| [29] |
Brockmeyer NH, Brucklacher U, Potthoff A, et al. Off-label use in dermatology in Germany: what has changed since 2004[J].J Dtsch Dermatol Ges,2009,7(11): 938-945.
|
| [30] |
Aguggia M, Cavallini M, Varetto L. Medical-legal issues in headache: penal and civil Italian legislation, working claims,social security, off-label prescription[J]. Neurol Sci, 2006,27 Suppl 2: S198-202.
|
| [31] |
Jacquin JP, Jones S, Magné N, et al. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials[J]. Breast Cancer Res Treat,2012,134(3): 903-913.
|
| [32] |
Yin W, Jiang Y, Shen Z, et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials[J].PLoS One,2011,6(6): e21030.
|
| [33] |
De Laurentiis M, Cancello G, D’Agostino D, et al. Taxanebased combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials[J]. J Clin Oncol,2008,26(1): 44-53.
|
| [34] |
Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis[J].Adv Ther,2013,30(10): 870-884.
|
| [35] |
余波.贝伐单抗与乳腺癌治疗[J]. 药品评价,2012, 9(6): 21-23.
|
| [36] |
von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer[J]. N Engl J Med,2012,366(4): 299-309.
|
| [37] |
刘韬,陈富钦,黄雪玲,等.贝伐珠单抗超说明书适应症用药情况调研[J]. 今日药学,2013,23(10): 667-671.
|
| [38] |
黄红艳,江泽飞,王涛,等. 贝伐珠单抗联合多西他赛治疗Her-2 阴性复发转移性乳腺癌的疗效观察[J]. 中国癌症杂志,2011,21(3): 220-224.
|
| [39] |
Osborne CK,Schiff R. Mechanisms of endocrine resistance in breast cancer[J].Annu Rev Med,2011,62: 233-247.
|
| [40] |
Gradishar WJ, Anderson BO, Blair SL, et al. Breast cancer version 3.2014[J]. J Natl Compr Canc Netw,2014, 12(4): 542-590.
|
| [41] |
Holt GR. Declaration of Helsinki-the world’ s document of conscience and responsibility [ J]. South Med J, 2014,107(7): 407.
|
| [42] |
Jung K, LePendu P, Chen WS, et al. Automated detection of off-label drug use[J]. PLoS One,2014,9(2): e89324.
|
| [43] |
Jung K, Lependu P, Shah N. Automated detection of systematic off-label drug use in free text of electronic medical records[J]. AMIA Jt Summits Transl Sci Proc, 2013, 2013: 94-98.
|